EP3414692A4 - HIGH-PERFORMANCE IDENTIFICATION OF PATIENT-SPECIFIC NEOEPITOPES AS THERAPEUTIC TARGETS FOR CANCER IMMUNOTHERAPIES - Google Patents

HIGH-PERFORMANCE IDENTIFICATION OF PATIENT-SPECIFIC NEOEPITOPES AS THERAPEUTIC TARGETS FOR CANCER IMMUNOTHERAPIES Download PDF

Info

Publication number
EP3414692A4
EP3414692A4 EP17750909.8A EP17750909A EP3414692A4 EP 3414692 A4 EP3414692 A4 EP 3414692A4 EP 17750909 A EP17750909 A EP 17750909A EP 3414692 A4 EP3414692 A4 EP 3414692A4
Authority
EP
European Patent Office
Prior art keywords
patient
therapeutic targets
cancer immunotherapies
performance identification
specific neoepitopes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17750909.8A
Other languages
German (de)
French (fr)
Other versions
EP3414692A1 (en
Inventor
Andrew Nguyen
John Zachary Sanborn
Stephen Charles BENZ
Kayvan Niazi
Shahrooz Rabizadeh
Patrick Soon-Shiong
Charles Joseph VASKE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nant Holdings IP LLC
Nantomics LLC
Original Assignee
Nant Holdings IP LLC
Nantomics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nant Holdings IP LLC, Nantomics LLC filed Critical Nant Holdings IP LLC
Publication of EP3414692A1 publication Critical patent/EP3414692A1/en
Publication of EP3414692A4 publication Critical patent/EP3414692A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
EP17750909.8A 2016-02-12 2017-02-10 HIGH-PERFORMANCE IDENTIFICATION OF PATIENT-SPECIFIC NEOEPITOPES AS THERAPEUTIC TARGETS FOR CANCER IMMUNOTHERAPIES Withdrawn EP3414692A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662294665P 2016-02-12 2016-02-12
PCT/US2017/017549 WO2017139694A1 (en) 2016-02-12 2017-02-10 High-throughput identification of patient-specific neoepitopes as therapeutic targets for cancer immunotherapies

Publications (2)

Publication Number Publication Date
EP3414692A1 EP3414692A1 (en) 2018-12-19
EP3414692A4 true EP3414692A4 (en) 2020-07-29

Family

ID=59564011

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17750909.8A Withdrawn EP3414692A4 (en) 2016-02-12 2017-02-10 HIGH-PERFORMANCE IDENTIFICATION OF PATIENT-SPECIFIC NEOEPITOPES AS THERAPEUTIC TARGETS FOR CANCER IMMUNOTHERAPIES

Country Status (12)

Country Link
US (2) US11361841B2 (en)
EP (1) EP3414692A4 (en)
JP (1) JP2019511907A (en)
KR (1) KR20180091119A (en)
CN (1) CN108701172A (en)
AU (1) AU2017217877A1 (en)
CA (1) CA3014252A1 (en)
IL (1) IL261090A (en)
MX (1) MX2018009804A (en)
SG (1) SG11201806282XA (en)
TW (1) TW201739919A (en)
WO (1) WO2017139694A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6384930B2 (en) * 2014-03-25 2018-09-05 ファイブスリー ジェノミックス， エルエルシーＦｉｖｅ３ Ｇｅｎｏｍｉｃｓ， Ｌｌｃ System and method for RNA analysis in function verification of oncogene mutations
WO2017139694A1 (en) 2016-02-12 2017-08-17 Nantomics, Llc High-throughput identification of patient-specific neoepitopes as therapeutic targets for cancer immunotherapies
SG11201811564QA (en) 2016-06-29 2019-01-30 Tesaro Inc Methods of treating ovarian cancer
CA3058807A1 (en) 2017-04-03 2018-10-11 Biontech Us Inc. Protein antigens and uses thereof
US11646103B2 (en) 2017-09-06 2023-05-09 Nant Holdings Ip, Llc HLA tissue matching and methods therefor
EP3688165A4 (en) 2017-09-25 2021-09-29 Nant Holdings IP, LLC NEO-EPITOPE PRESENTATION VALIDATION
TW201930340A (en) 2017-12-18 2019-08-01 美商尼恩醫療公司 Neoantigens and uses thereof
US20210106574A1 (en) * 2017-12-27 2021-04-15 Tesaro, Inc. Methods of Treating Cancer
EP3775258A4 (en) 2018-03-28 2022-01-26 Board of Regents, The University of Texas System IDENTIFICATION OF EPIGENETIC ALTERATIONS IN DNA ISOLATED FROM EXOSOMES
MX2020014243A (en) 2018-06-19 2021-05-12 Biontech Us Inc NEOANTIGENS AND THEIR USES.
CA3106564A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for breast cancer
US20220349010A1 (en) 2018-07-26 2022-11-03 Frame Pharmaceuticals B.V. Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
CN109021062B (en) * 2018-08-06 2021-08-20 倍而达药业（苏州）有限公司 A screening method for tumor neoantigens
WO2020033585A1 (en) * 2018-08-07 2020-02-13 The Broad Institute, Inc. Methods for combinatorial screening and use of therapeutic targets thereof
CN113507935A (en) * 2018-10-16 2021-10-15 得克萨斯州大学系统董事会 Identification and targeting of pathogenic extracellular matrix for diagnosis and treatment of cancer and other diseases
GB201817651D0 (en) * 2018-10-29 2018-12-12 Univ College Dublin Nat Univ Ireland Dublin Method for predicting effectiveness of treatments for cancer patients
WO2020092038A1 (en) * 2018-10-31 2020-05-07 Nantomics, Llc Cdkn2a screening germline expression
CN109438570B (en) * 2018-11-28 2021-07-20 生命谷（海南）生物科技股份有限公司 FGFR3 mutant short peptide of tumor-related gene and application thereof
CN113272419A (en) * 2018-12-04 2021-08-17 南托米克斯有限责任公司 Method for preparing therapeutic T lymphocyte
WO2020176726A1 (en) * 2019-02-27 2020-09-03 Epivax Oncology, Inc. Improved compositions and methods for personalized neoplasia vaccines
CN110286235B (en) * 2019-07-10 2022-07-15 郑州大学 A combined detection serum marker, kit and detection method for early screening and diagnosis of liver cancer
JP7617574B2 (en) * 2020-01-07 2025-01-20 コリア アドバンスド インスティテュート オブ サイエンス アンド テクノロジー Method and system for screening neoantigens and use thereof
CN112980948B (en) * 2020-08-28 2023-03-21 中山大学附属口腔医院 Application of NFAT3 as therapeutic target in screening or preparing head and neck squamous cell carcinoma drugs
CN112725454B (en) * 2021-02-03 2021-08-03 山东第一医科大学附属省立医院(山东省立医院) A prognostic model for overall survival in patients with bladder cancer
CN113755594B (en) * 2021-09-26 2024-05-14 中国医学科学院肿瘤医院 System and application for predicting benefit of auxiliary chemotherapy of small cell lung cancer and identifying chemotherapy drug resistance treatment target point
CN118561958B (en) * 2024-05-20 2025-07-22 江苏海洋大学 Lung cancer new antigen polypeptide and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014168874A2 (en) * 2013-04-07 2014-10-16 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
WO2015095811A2 (en) * 2013-12-20 2015-06-25 The Board Institute Inc. Combination therapy with neoantigen vaccine
WO2016172722A1 (en) * 2015-04-23 2016-10-27 Nantomics, Llc Cancer neoepitopes
US20170028043A1 (en) * 2015-10-12 2017-02-02 Nantomics, Llc Iterative Discovery Of Neoepitopes And Adaptive Immunotherapy And Methods Therefor

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9575070B2 (en) 2001-12-04 2017-02-21 Wayne State University Neoepitope detection of disease using protein arrays
US8614169B2 (en) * 2001-12-04 2013-12-24 Wayne State University Neoepitope detection of disease using protein arrays
US7664689B1 (en) 2003-06-24 2010-02-16 Evercom Systems, Inc. Systems and methods for transaction and information management
US20030232340A1 (en) * 2002-06-13 2003-12-18 David Anderson Nanoporous particle with a retained target
MXPA05005051A (en) 2002-11-12 2006-03-10 Albert B Deisseroth Adenoviral vector vaccine.
DK1601450T3 (en) 2003-03-10 2013-09-08 Expression Pathology Inc Liquid tissue preparation from histopathologically processed biological samples, tissues and cells
ES2425749T3 (en) * 2004-03-31 2013-10-17 The General Hospital Corporation Method for determining the response of cancer to treatments directed at the epidermal growth factor receptor
CN101039953B (en) * 2004-07-23 2012-08-15 沃尔特及伊莱萨霍尔医学研究院 Therapeutic and diagnostic agents
JP2008535868A (en) * 2005-04-14 2008-09-04 ザ ユニバーシティー オブ クイーンズランド Immunomodulatory composition and uses therefor
EP2569633B1 (en) 2010-05-14 2016-02-10 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
KR102042253B1 (en) 2010-05-25 2019-11-07 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Bambam: parallel comparative analysis of high-throughput sequencing data
US9646134B2 (en) 2010-05-25 2017-05-09 The Regents Of The University Of California Bambam: parallel comparative analysis of high-throughput sequencing data
JP2013538211A (en) * 2010-08-23 2013-10-10 セレクタ バイオサイエンシーズ インコーポレーテッド Targeted multi-epitope dosage forms that elicit an immune response to an antigen
WO2014012051A1 (en) * 2012-07-12 2014-01-16 Persimmune, Inc. Personalized cancer vaccines and adoptive immune cell therapies
AU2013289883B2 (en) * 2012-07-13 2018-11-01 Zymeworks Bc Inc. Bispecific asymmetric heterodimers comprising anti-CD3 constructs
US20170017749A1 (en) 2015-07-15 2017-01-19 International Business Machines Corporation System and method for identifying cancer driver genes
AU2016311444B2 (en) 2015-08-25 2019-02-07 Nantomics, Llc Systems and methods for high-accuracy variant calling
CA3003251A1 (en) 2015-10-12 2017-04-20 Nantomics, Llc Systems, compositions, and methods for discovery of msi and neoepitopes that predict sensitivity to checkpoint inhibitors
WO2017139694A1 (en) 2016-02-12 2017-08-17 Nantomics, Llc High-throughput identification of patient-specific neoepitopes as therapeutic targets for cancer immunotherapies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014168874A2 (en) * 2013-04-07 2014-10-16 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
WO2015095811A2 (en) * 2013-12-20 2015-06-25 The Board Institute Inc. Combination therapy with neoantigen vaccine
WO2016172722A1 (en) * 2015-04-23 2016-10-27 Nantomics, Llc Cancer neoepitopes
US20170028043A1 (en) * 2015-10-12 2017-02-02 Nantomics, Llc Iterative Discovery Of Neoepitopes And Adaptive Immunotherapy And Methods Therefor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
N. HACOHEN ET AL: "Getting Personal with Neoantigen-Based Therapeutic Cancer Vaccines", CANCER IMMUNOLOGY RESEARCH, vol. 1, no. 1, 7 April 2013 (2013-04-07), pages 11 - 15, XP055111441, ISSN: 2326-6066, DOI: 10.1158/2326-6066.CIR-13-0022 *
See also references of WO2017139694A1 *
YONG-CHEN LU ET AL: "Cancer immunotherapy targeting neoantigens", SEMINARS IN IMMUNOLOGY., vol. 28, no. 1, 30 November 2015 (2015-11-30), US, pages 22 - 27, XP055364718, ISSN: 1044-5323, DOI: 10.1016/j.smim.2015.11.002 *

Also Published As

Publication number Publication date
US20220270709A1 (en) 2022-08-25
IL261090A (en) 2018-10-31
AU2017217877A1 (en) 2018-08-16
KR20180091119A (en) 2018-08-14
TW201739919A (en) 2017-11-16
SG11201806282XA (en) 2018-08-30
JP2019511907A (en) 2019-05-09
EP3414692A1 (en) 2018-12-19
WO2017139694A1 (en) 2017-08-17
CN108701172A (en) 2018-10-23
MX2018009804A (en) 2018-11-09
CA3014252A1 (en) 2017-08-17
US20190034582A1 (en) 2019-01-31
US11361841B2 (en) 2022-06-14

Similar Documents

Publication Publication Date Title
EP3414692A4 (en) HIGH-PERFORMANCE IDENTIFICATION OF PATIENT-SPECIFIC NEOEPITOPES AS THERAPEUTIC TARGETS FOR CANCER IMMUNOTHERAPIES
MA43374A (en) METHODS OF TREATMENT OF MALIGNANT TUMORS
PL3283527T3 (en) COMBINED TREATMENT OF CANCER
IL268676A (en) Inhibition of SMARCA2 for cancer therapy
EP4112738C0 (en) MULTIGEN ANALYSIS OF TUMOR SAMPLES
IL249065A0 (en) Combination of treatments for cancer treatment
LT3277842T (en) METHODS OF TREATMENT OF CANCER PATIENTS WITH PHARNEZYL TRANSFERSHIP INHIBITORS
IL252361A0 (en) Preparations and methods for the treatment and diagnosis of cancers resistant to chemotherapy
HUE054397T2 (en) Antibody preparations for tumor treatment
IL251890A0 (en) An integrated immunotherapy approach to cancer treatment
HUE054012T2 (en) Combination therapy for cancer
PL3455631T3 (en) METHODS OF CLASSIFICATION OF PATIENTS WITH SOLID CANCER
EP3553087C0 (en) TARGETED THERAPY FOR LUNG CANCER
PL3377516T3 (en) COMPOSITION FOR TREATMENT OF CANCER
IL254876A0 (en) Treatment of lung cancer with glutaminase inhibitors
IL263802A (en) Combinations of cancer treatments
IL284875A (en) Zofoxifene treatment for breast cancer
IL258521B1 (en) Combination of treatments for cancer treatment
IL264203A (en) Selection of neoepitopes as disease-specific targets for therapy with increased efficacy
PT3458052T (en) COMBINED TREATMENT OF CANCER
BR112016027041A2 (en) PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF CANCER
EP3413927A4 (en) Cancer Therapy
IL264589A (en) Combined treatment for pancreatic cancer
LT3576740T (en) TREATMENT OF CANCER
LT3534885T (en) PHARNESYL TRANSANSERASE INHIBITORS FOR THE TREATMENT OF CANCER

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180726

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/00 20060101ALI20200219BHEP

Ipc: C12Q 1/68 20180101AFI20200219BHEP

Ipc: G01N 33/569 20060101ALI20200219BHEP

Ipc: A61K 39/395 20060101ALI20200219BHEP

Ipc: G01N 33/68 20060101ALI20200219BHEP

Ipc: A61K 35/17 20150101ALI20200219BHEP

Ipc: A61K 48/00 20060101ALI20200219BHEP

Ipc: A61K 47/50 20170101ALI20200219BHEP

Ipc: G01N 33/574 20060101ALI20200219BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20200625

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/50 20170101ALI20200619BHEP

Ipc: G01N 33/68 20060101ALI20200619BHEP

Ipc: A61K 39/395 20060101ALI20200619BHEP

Ipc: G01N 33/569 20060101ALI20200619BHEP

Ipc: A61K 39/00 20060101ALI20200619BHEP

Ipc: G01N 33/574 20060101ALI20200619BHEP

Ipc: A61K 35/17 20150101ALI20200619BHEP

Ipc: C12Q 1/68 20180101AFI20200619BHEP

Ipc: A61K 48/00 20060101ALI20200619BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20210126